Morgan Stanley Cytosorbents Corp Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Cytosorbents Corp stock. As of the latest transaction made, Morgan Stanley holds 116,385 shares of CTSO stock, worth $100,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares

116,385

Previous 119,978 2.99%

Holding current value

$100,091

Previous $133,000 17.29%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.86 - $1.07 $3,089 - $3,844	-3,593 Reduced 2.99%	116,385 $110,000
Q4 2023 Feb 13, 2024	SELL	$1.08 - $1.94 $3,596 - $6,460	-3,330 Reduced 2.7%	119,978 $133,000
Q3 2023 Nov 15, 2023	SELL	$1.86 - $4.03 $355 - $769	-191 Reduced 0.15%	123,308 $231,000
Q2 2023 Aug 14, 2023	SELL	$2.37 - $3.65 $5,872 - $9,044	-2,478 Reduced 1.97%	123,499 $443,000
Q1 2023 May 15, 2023	BUY	$1.79 - $4.17 $26,194 - $61,023	14,634 Added 13.14%	125,977 $424,000

Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.63 $8,024 - $12,699	7,791 Added 7.52%	111,343 $172,000
Q3 2022 Nov 14, 2022	SELL	$1.39 - $2.46 $285,728 - $505,677	-205,560 Reduced 66.5%	103,552 $140,000
Q2 2022 Oct 27, 2022	BUY	$1.76 - $3.22 $207,262 - $379,196	117,763 Added 61.54%	309,112 $677,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.22 $207,262 - $379,196	117,763 Added 61.54%	309,112 $677,000
Q1 2022 Oct 27, 2022	SELL	$2.88 - $4.23 $339,157 - $498,137	-117,763 Reduced 38.1%	191,349 $610,000
Q1 2022 May 13, 2022	BUY	$2.88 - $4.23 $38,021 - $55,844	13,202 Added 7.41%	191,349 $610,000
Q4 2021 Feb 14, 2022	SELL	$4.05 - $8.11 $276,270 - $553,223	-68,215 Reduced 27.69%	178,147 $745,000
Q3 2021 Nov 15, 2021	BUY	$7.0 - $9.71 $1.72 Million - $2.39 Million	246,362 New	246,362 $2 Million

Others Institutions Holding CTSO

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About Cytosorbents Corp

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $37.5M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

More about CTSO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account